Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1

Conditions

Head and Neck Neoplasms 408Squamous Cell Carcinoma of Head and Neck 326Thyroid Neoplasms 104Carcinoma, Non-Small-Cell Lung 85Neoplasms 66Oropharyngeal Neoplasms 59Carcinoma, Squamous Cell 59Melanoma 56Lung Neoplasms 47Neoplasm Metastasis 44Mouth Neoplasms 43Breast Neoplasms 42Laryngeal Neoplasms 39Thyroid Cancer, Papillary 36Salivary Gland Neoplasms 35Colorectal Neoplasms 35Ovarian Neoplasms 33Carcinoma, Renal Cell 33Esophageal Neoplasms 32Urinary Bladder Neoplasms 30Stomach Neoplasms 30Tongue Neoplasms 28Nasopharyngeal Neoplasms 28Uterine Cervical Neoplasms 27Carcinoma 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 24Sarcoma 24Carcinoma, Medullary 24Recurrence 22

Interventions

spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Disorders of Sex Development × Head & Neck × Clear all
NCT02605967 2022-02-10

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Novartis

Phase 2 Completed
122 enrolled 28 charts
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Recurrence, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡